GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (CHIX:NSISBc) » Definitions » Other Current Receivables

Novonesis (Novozymes) B (CHIX:NSISBC) Other Current Receivables : kr1,015 Mil (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Novonesis (Novozymes) B Other Current Receivables?

Novonesis (Novozymes) B's Other Current Receivables for the quarter that ended in Mar. 2025 was kr1,015 Mil.

Novonesis (Novozymes) B's quarterly Other Current Receivables increased from Jun. 2024 (kr890.40 Mil) to Dec. 2024 (kr1,036.62 Mil) but then stayed the same from Dec. 2024 (kr1,036.62 Mil) to Mar. 2025 (kr1,015.13 Mil).

Novonesis (Novozymes) B's annual Other Current Receivables declined from Dec. 2022 (kr510.22 Mil) to Dec. 2023 (kr348.82 Mil) but then increased from Dec. 2023 (kr348.82 Mil) to Dec. 2024 (kr1,036.62 Mil).

Novonesis (Novozymes) B Other Current Receivables Historical Data

The historical data trend for Novonesis (Novozymes) B's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Other Current Receivables Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 217.95 558.92 510.22 348.82 1,036.62

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 348.82 - 890.40 1,036.62 1,015.13

Novonesis (Novozymes) B Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Novonesis (Novozymes) B Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (CHIX:NSISBc) » Definitions » Other Current Receivables
Comparable Companies
OCSE:SPG OCSE:FLUG B OCSE:HOVE LIN XPAR:AI SHW ECL APD ISX:TPIA XSWX:GIVN XSWX:SIKA XAMS:DSFIR DD BOM:500820 PPG SHSE:600309 ADX:BOROUGE IFF NSE:PIDILITIND LYB
Traded in Other Exchanges
NVZMY:USA NVZMF:USA 0Q4U:UK NSIS B:Denmark NZM:Germany NZM:Germany NZM2:Germany NZM2:Germany NZYM:Austria
Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Website
https://www.novozymes.com
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines